Psilocybin Therapy Guide
12 min readRead →
Cluster headaches are widely described as one of the most intensely painful human experiences — worse than childbirth or kidney stones, occurring in attacks multiple times per day for weeks or months. Conventional treatments fail more than half of patients. Here's what the clinical and patient evidence shows about psilocybin.
Cluster headache affects approximately 1 in 1,000 people. Attacks last 15–180 minutes and recur up to 8 times daily during a cluster period, which typically lasts weeks to months. The International Cluster Headache Questionnaire describes it as one of the most intensely painful human conditions known to medicine. Verapamil — the first-line preventive treatment — fails more than half of patients. This gap has driven a remarkable patient-led research movement and, more recently, formal clinical trials.
| Study | Design | Key Finding | Evidence |
|---|---|---|---|
| Schindler et al., 2022 Yale — RCT pilot | RCT, double-blind, placebo-controlled; 10 mg/70kg psilocybin, 3-dose pulse | Nonsignificant reduction in primary outcome; informative for extension phase design | Early |
| Schindler et al., 2024 Yale — blinded extension | Blinded extension of RCT; repeat psilocybin pulse ≥6 months after first round | Repeat pulse significantly reduced cluster attack frequency by approximately 50%; effect sustained over 8 weeks in chronic patients | Emerging |
| Madsen et al., 2024 Copenhagen — open-label | Open-label; 3 psilocybin doses over 3 weeks; chronic cluster headache; n=10 | Significant reduction in headache frequency and mean self-rated pain at 4 weeks; reductions correlated with hypothalamic functional connectivity changes on fMRI | Emerging |
| PEACE Trial, 2025–ongoing George Institute, Australia | RCT, placebo-controlled; 10 mg psilocybin weekly × 4 weeks; episodic + chronic | Ongoing; first new approved cluster headache trial in Australia in two decades; funded by Australian Medical Research Future Fund | Early |
| Schindler et al., 2025 Neurology (secondary analysis) | Secondary analysis across migraine and cluster headache trials | Headache frequency changes after psilocybin were independent of acute psychedelic effects and measures of mental health — suggesting direct neurological action | Emerging |
Long before clinical trials, cluster headache patients independently discovered that small doses of psilocybin mushrooms or LSD could abort attacks and — more remarkably — terminate entire cluster periods. This observation, circulating online since the late 1990s, was formalized by the Clusterbusters patient advocacy organization, which has collected and shared patient experiences for two decades.
A 2015 survey by Schindler et al. published in the Journal of Psychoactive Drugs formally documented the phenomenon: approximately 50–80% of cluster headache patients who tried classic psychedelics reported benefit. The most striking finding was that sub-psychedelic doses — far lower than recreational amounts — were reported to be sufficient. This distinguishes the cluster headache application from psilocybin's antidepressant effects, which appear to depend on the intensity of the acute experience.
The Clusterbusters survey also found that patients using psilocybin reported better outcomes than those using conventional treatments, including verapamil, lithium, and steroids — with fewer side effects. These are patient self-reports, not controlled data, and must be interpreted accordingly. But the consistency and specificity of the observations drove Yale's Schindler to begin formal clinical investigation.
The Clusterbusters survey data is compelling and directionally consistent with subsequent trial findings — but it is not controlled evidence. Selection bias, placebo effects, and the natural episodic remission pattern of cluster headaches (periods can end spontaneously) can all inflate apparent benefits in uncontrolled reports. Formal RCTs are necessary and ongoing.
The mechanism of psilocybin in cluster headache is one of the most scientifically interesting aspects of psychedelic medicine — because it appears to operate through a fundamentally different pathway than its antidepressant effects.
The strongest clue is the finding by Schindler et al. (Neurology, 2025) that headache frequency changes after psilocybin were statistically independent of the intensity of the acute psychedelic experience and of measures of mental health. This directly challenges the standard psychedelic therapy model — in which the mystical or emotional experience is thought to be the active therapeutic ingredient — and suggests psilocybin is acting directly on the neurological substrate of cluster headache.
The Yale team conducted the first formal randomised controlled investigation of psilocybin in cluster headache. The pilot study (published Headache, 2022) randomised 14 participants to a 3-dose pulse of psilocybin (10 mg/70 kg, doses 5 days apart) or placebo. The primary outcome was negative — likely due to the small sample size. However, the blinded extension phase (published Journal of Neurological Sciences, 2024) offered key new data: participants who returned for a repeat psilocybin pulse at least 6 months after the first round showed a statistically significant approximately 50% reduction in cluster attack frequency, sustained over 8 weeks. The extension finding is notable because it was statistically significant where the primary study was not, and because prior psilocybin response did not predict subsequent response.
The Copenhagen trial enrolled 10 chronic cluster headache patients who received three psilocybin doses over three weeks (same pulse-style regimen as Yale). The open-label design limits conclusions, but results showed significant reductions in headache frequency and mean self-rated pain intensity at 4 weeks. The study's most important contribution was the fMRI data: attack frequency reductions correlated with hypothalamic functional connectivity changes — providing the first neural biomarker evidence for the mechanism in cluster headache.
The Psilocybin Efficacy and Acceptability on Cluster Headache Episodes trial, funded by Australia's Medical Research Future Fund, is the first new approved cluster headache trial in Australia in over two decades. Led by Dr. Faraidoon Haghdoost at the George Institute for Global Health and UNSW Sydney, it will study 10 mg psilocybin once weekly for four weeks versus placebo in episodic and chronic cluster headache patients. Results are expected 2026–2027. This is a significant step — Australia in 2023 became the first country to formally legalise psilocybin for clinical use, giving Australian researchers access to the compound under an established regulatory framework.
The cluster headache dosing protocol is fundamentally different from psilocybin's use in depression or PTSD — and this distinction matters for safety and access.
Clinical trials have used a pulse regimen: typically 3 doses of psilocybin administered approximately 5 days apart. Each dose in the Yale trial was approximately 10 mg psilocybin (~0.14 mg/kg) — mildly psychedelic in most people, substantially below the 25 mg doses used in depression trials.
Patient self-reports from Clusterbusters surveys describe benefit with doses as low as 0.5–1g dried mushroom — which contains roughly 5–10 mg psilocybin. Many patients describe "micro-busting": intentionally staying below the threshold of a full psychedelic experience while achieving headache prevention. This is consistent with the trial finding that effect does not correlate with psychedelic intensity.
Cluster headache patients self-medicating with psilocybin — a common reality given the severity of the condition and limited conventional options — face the risks of any unsupervised psychedelic use: psychological distress, dangerous environments, cardiovascular events, and interactions with medications. The evidence for benefit does not constitute a recommendation to self-treat. Always consult a clinician. See safe trip guide and dosage page.
Psilocybin has no FDA approval for cluster headache and no Breakthrough Therapy designation for this indication. Legal access pathways are limited but broader than for OCD, partly because Oregon and Colorado programs do not restrict by diagnosis.
Search clinicaltrials.gov for "psilocybin cluster headache" — the PEACE trial (Australia) and any US follow-on to the Yale extension study are the most relevant active investigations. US-based trials have been limited by the difficulty of recruiting for a relatively rare condition and the lack of commercial funding (psilocybin is a non-proprietary compound with no patent protection).
Oregon and Colorado's state-regulated psilocybin programs allow supervised adult use without requiring a specific medical diagnosis. Cluster headache patients may legally access supervised sessions in these states. This is not a clinical treatment protocol, but the low-dose, supervised setting aligns reasonably well with the evidence base. See Retreats and Legal Status for the full picture.
Switzerland permits psilocybin under compassionate use provisions — several dozen authorized physicians may prescribe it, including for cluster headache (Leighton et al., 2025). Canada's Special Access Program has approved at least one cluster headache patient. Australia's TGA allows authorized psychiatrists to prescribe psilocybin since July 2023 — the PEACE trial is building on this framework.